From Zacks Research: The biotech sector has had a rough start to the year with the NASDAQ Biotechnology Index declining approximately 16% year-to-date. Sector-specific issues like increasing political and media focus on high price tags for new drugs and the changing competitive scenario have been weighing on biotech stocks over the last few quarters.
NASDAQ:IBB, NASDAQ:GILD, NASDAQ:BIB, NASDAQ:CELG
NASDAQ:AMGN, NASDAQ:GILD, NASDAQ:BIIB, NASDAQ:CELG
Abby Higgs: ETF investing is so popular because of its ease and safety – but you might feel like the amount of choices in exchange-traded funds can be overwhelming.
NASDAQ:NVAX, NASDAQ:BIIB, NASDAQ:CELG, NASDAQ:GILD
NASDAQ:GILD, NASDAQ:CELG, NASDAQ:BIIB
NYSEARCA:XBI, NASDAQ:GILD, NASDAQ:IBB